Cohen & Steers
CNS | NYSE
$69.97
-$1.38 (-1.93%)
At close: Nov 16, 2026, 4:00 PM ET
$69.97
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:01 PM ET
Cohen & Steers Company Profile
Company profile explainedCompany Profile
Cohen & Steers, Inc. operates as a publicly traded holding company specializing in asset management. Through its various operating units, the firm delivers financial services to institutional investors, such as pension funds, university endowments, and charitable foundations. Its subsidiaries are tasked with managing bespoke client portfolios across equities, fixed income, multi-asset strategies, and commodities. Additionally, these subsidiaries develop and oversee a diverse range of investment vehicles, including mutual funds (focused on equity, fixed income, balanced, and multi-asset classes) and hedge funds. The company's global investment strategy, implemented via its affiliated entities, involves allocating capital in public equity, fixed income, and commodity markets. For its equity and fixed income allocations, the firm's affiliates specifically target businesses within the real estate industry (including REITs), infrastructure, and natural energy resources. Preferred securities also constitute a part of its fixed income portfolios. Established in 1986, Cohen & Steers, Inc. maintains its primary base in New York, with international branch offices in London (UK), Central (Hong Kong), Tokyo (Japan), and Seattle (Washington).
Key Executives
| Name | Position |
|---|---|
| Joseph Harvey | Chief Executive Officer & Director |
| Adam Derechin | Executive Vice President & Chief Operating Officer |
| Amit Muni | Chief Financial Officer |
| Daniel Noonan | Executive Vice President & Head of Global Distribution |
| Elena Dulik | Chief Accounting Officer & Senior Vice President |
| Francis Poli | Executive Vice President, General Counsel & Secretary |
| Jon Cheigh | President & Chief Investment Officer |
| Martin Cohen | Co-Founder & Chairman |
| Robert Hamilton Steers | Founder & Executive Chairman |
| Robert Klemens | Vice President of Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | 10-Q | Quarterly Report |
| Oct 15, 2026 | 8-K | Current Report |
| Oct 07, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 07, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
Cohen & Steers
| Country | United States |
| IPO Date | Aug 16, 2004 |
| Industry | Asset Management |
| Sector | Financial Services |
| Employees | 424 |
| CEO | Joseph Martin Harvey |
Contact Details
1166 Avenue of the Americas New York City,
New York 10036 United States
Stock Details
| Ticker Symbol | CNS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001284812 |
| CUSIP Number | 19247A100 |
| ISIN Number | US19247A1007 |
| SIC Code | 6282 |
Recent News
- 3 days ago / prnewswire.comCohen & Steers Announces Changes to Realty Indexes
- 4 days ago / globenewswire.comPraxis Precision Medicines Details Launch Readiness for Relutrigine and Ulixacaltamide and Outlines Expanded Pipeline in Preparation to be the Preeminent CNS Biotech at Investor Day
- 6 days ago / prnewswire.comCohen & Steers and DLC Acquire West Street Shopping Center in Keene, New Hampshire
- 7 days ago / prnewswire.comCohen & Steers Announces Preliminary Assets Under Management and Net Flows for October 2026
- 13 days ago / prnewswire.comCorero Network Security Accelerates International Growth with Strategic Investment in Regional Leadership and Partnerships
- 18 days ago / globenewswire.comIntegra LifeSciences to Highlight Hands-On Education and Neurosurgery Innovation at CNS 2026 Annual Meeting
- 18 days ago / prnewswire.comCohen & Steers, Inc. Declares Quarterly Dividend
- 20 days ago / businesswire.comLG CNS and D-Wave Announce Strategic Relationship to Advance Quantum Optimization Adoption in South Korea
- 29 days ago / fool.comCohen & Steers: 3 Key Takeaways for Long-Term Investors
- 29 days ago / businesswire.comZipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases
Add to Watchlist
Select watchlists to add or remove CNS